Opioid receptor
Assets acting on this target.
- Class
- Topical opioid antagonist
Related mechanisms
Kappa-opioid receptor (agonist, peripherally restricted) (2)Kappa-opioid receptor (inhibitor) (2)Opioid receptors (mu-opioid receptor) (2)Dopamine D2 and serotonin 5-HT2A/5-HT2C receptors (antagonist); mu-opioid receptor (antagonist) (1)Dopamine D2 and serotonin 5-HT2A receptors (antagonist); mu-opioid receptor (antagonist) (1)Kappa-opioid receptor (agonist); mu-opioid receptor (antagonist) (1)
Opioid receptor drugs compared
4 drugs, stage by indication
| Drug | Developer | Modality | Furthest stage | Stage by indication |
|---|---|---|---|---|
| nalmefene nasal sprayOPVEE | Indivior Pharmaceuticals, Inc. | small molecule | Approved | Approved in Opioid Overdose Reversal |
| Naloxone (Narcan)Narcan | Emergent BioSolutions | small molecule | Approved | Approved in Opioid Overdose |
| Naltrexone (Vivitrol) | Alkermes plc | small molecule (extended-release injectable) | Approved | Approved in Opioid and Alcohol Dependence |
| Naltrexone/Acetaminophen (ALLOD-2) | Allodynic Therapeutics, LLC | Not recorded | Phase 2/3 | Phase 2/3 in Migraine |